Teresa López Fernández

TL;DR: This document describes the development and use of angiotensin-converting enzyme, a non-volatile substance that acts as a “spatially aggregating substance” to reduce the chances of heart attack in women.

TL;DR: No abstract available Keywords: European Society of Cardiology; arrhythmias; cancer therapy; cardio-oncology; cardiotoxicity; chemotherapy; early detection; ischaemia; myocardial dysfunction; surveillance.

TL;DR: Novel surveillance clinical pathways integrating cardiac biomarkers for cancer patients receiving anthracycline chemotherapy or trastuzumab biomarkers are presented and future direction in cardio‐oncology biomarker research is discussed.

TL;DR: The majority of patients present objective data of myocardial injury/dysfunction during or after cancer therapy, but severe CTox, with a strong prognostic relationship, was comparatively rare and should be reflected in protocols for clinical and research practices.